Question · asked by 1 review
Levomepromazine vs Typical antipsychotics: Acceptability of treatment ‐ leaving the study early
- Population
- patients with schizophrenia
- Intervention
- Levomepromazine
- Comparison
- Typical antipsychotics
- Outcome
- Acceptability of treatment ‐ leaving the study early
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ long term ‐ any reason · patients with schizophrenia Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty). Levomepromazine for schizophrenia (2010) · Cochrane Headline outcomes only | RR 0.4 [0.09, 1.81] | 1 study · 38 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.